Companies in #Endocrinology

Global biotechnology company developing and commercializing innovative therapies for rare genetic diseases.

Crinetics Pharmaceuticals is a public biopharmaceutical company developing and commercializing oral, small-molecule therapies for endocrine diseases and endocrine-related tumors.

Oxford University spin-out applying high-resolution native mass spectrometry through its OdyssION platform to drug membrane proteins and intracellular complexes that have historically been undruggable, with small-molecule programs in orphan endocrine and immunological disease.

Commercial-stage rare disease biopharmaceutical company focused on melanocortin-4 receptor (MC4R) pathway therapeutics; lead product IMCIVREE (setmelanotide) treats hyperphagia and severe obesity caused by POMC, PCSK1, LEPR and Bardet-Biedl syndrome deficiencies.

Sling Therapeutics is a clinical-stage biopharmaceutical company in Ann Arbor, Michigan developing linsitinib, the first and only late-stage oral small-molecule IGF-1R inhibitor for the treatment of thyroid eye disease (TED).

Clinical-stage biotechnology company developing first-in-class MUC1-C-targeted immuno-oncology therapeutics along with diagnostics and formulations for endocrine disorders. Its lead antibody-drug conjugate XYA02 has FDA orphan drug designation in gastric cancer and dosed its first patient in September 2026.

Copenhagen-based peptide-based medicines company developing treatments for metabolic and endocrine diseases, including glepaglutide for short bowel syndrome.